A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
pixel

ARTL Insider Trading

Insider Ownership Percentage: 3.51%
Insider Buying (Last 12 Months): $4,836.00
Insider Selling (Last 12 Months): $0.00

Artelo Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Artelo Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Artelo Biosciences Share Price & Price History

Current Price: $3.45
Price Change: +0.30 (1.20%)
As of 09/30/2022 01:00 AM ET

This chart shows the closing price history over time for ARTL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Artelo Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2022Gregory D. GorgasCEOBuy1,200$4.03$4,836.001,200View SEC Filing Icon  
4/16/2021Gregory D. GorgasCEOBuy8,500$1.15$9,775.00270,676View SEC Filing Icon  
5/15/2020Gregory D. GorgasCEOBuy4,200$1.22$5,124.00
5/4/2020Connie MatsuiDirectorBuy41,667$1.27$52,917.09
5/4/2020Gregory D. GorgasCEOBuy4,167$1.27$5,292.09
11/4/2019Gregory D. GorgasCEOBuy2,400$2.05$4,920.00
11/1/2019Gregory D. GorgasCEOBuy7,600$2.18$16,568.00
10/15/2019Gregory D. GorgasCEOBuy2,600$2.45$6,370.00
10/11/2019Gregory D. GorgasCEOBuy2,700$1.96$5,292.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Artelo Biosciences (NASDAQ:ARTL)

49.66% of Artelo Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARTL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Artelo Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Renaissance Technologies LLC182,619$82K0.0%+67.8%0.432%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.683,896$0.31M0.0%-23.2%1.617%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC22,594$27K0.0%-85.3%0.092%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC556,738$0.66M0.0%N/A2.273%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.862,172$1.03M0.0%+247.5%3.520%Search for SEC Filing on Google Icon
8/12/2021Penserra Capital Management LLC28,427$27K0.0%N/A0.116%Search for SEC Filing on Google Icon
8/11/2021Bank of New York Mellon Corp86,603$0.10M0.0%-15.4%0.354%Search for SEC Filing on Google Icon
8/6/2021HighTower Advisors LLC62,000$74K0.0%N/A0.253%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC153,769$0.25M0.0%N/A0.664%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC180,814$0.30M0.0%N/A0.781%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC21,108$34K0.0%N/A0.091%Search for SEC Filing on Google Icon
5/13/2021Kepos Capital LP200,000$0.33M0.0%-20.0%0.864%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp102,390$0.17M0.0%N/A0.442%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC141,273$0.23M0.0%+132.1%0.610%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG15,675$26K0.0%N/A0.068%Search for SEC Filing on Google Icon
4/6/2021LVM Capital Management Ltd. MI20,000$33K0.0%N/A0.127%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Artelo Biosciences logo
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Read More on Artelo Biosciences

Today's Range

Now: $3.45
Low: $3.39
High: $3.50

50 Day Range

MA: $5.41
Low: $3.19
High: $60.00

52 Week Range

Now: $3.45
Low: $3.11
High: $19.80

Volume

10,919 shs

Average Volume

44,933 shs

Market Capitalization

$9.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Who are the company insiders with the largest holdings of Artelo Biosciences?

Artelo Biosciences' top insider shareholders include:
  1. Gregory D Gorgas (CEO)
Learn More about top insider investors at Artelo Biosciences.
Market Wizard Reveals: The One Ticker Retirement Plan
Introducing the “One Ticker Retirement Plan”… It’s a way to trade just one ticker…

And potentially make all the money you need – no matter what happens in the stock market.

Sounds too good to be true?
Larry reveals everything in this interview